Comparative Pharmacology
Head-to-head clinical analysis: NICLOCIDE versus VERMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICLOCIDE versus VERMIDOL.
NICLOCIDE vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category C
Category C
Anthelmintic
Anthelmintic